Skip to main content

Market Overview

AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration

Share:
AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration
  • AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery collaboration.
  • Under the agreements' financial terms, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties. 
  • Under the new agreement, AbCellera will generate panels of antibodies for up to eight new targets selected by Gilead.
  • The expanded collaboration will leverage AbCellera's fully humanized antibodies using the Trianni Mouse platform and the OrthoMab protein engineering platform.
  • Price Action: GILD shares increased 1.75% at $65.74, and ABCL shares are up 8.33% at $36.79 on the last check Thursday.
 

Related Articles (GILD + ABCL)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com